John Rakow - Jun 3, 2022 Form 3 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role: SVP, Genl Counsel, Acting CFO
Signature: John Rakow, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol: ADVM
Transactions as of: Jun 3, 2022
Transactions value $: $0
Form type: 3
Date filed: 6/10/2022, 04:37 PM
Next filing: Jun 10, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ADVM	Common Stock						58.2K	Jun 3, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ADVM	Stock Option (Right to Buy)							Jun 3, 2022	Common Stock	125K	$11.72	Direct	F1
holding	ADVM	Stock Option (Right to Buy)							Jun 3, 2022	Common Stock	15.5K	$13.44	Direct	F2
holding	ADVM	Stock Option (Right to Buy)							Jun 3, 2022	Common Stock	50K	$3.09	Direct	F3
holding	ADVM	Stock Option (Right to Buy)							Jun 3, 2022	Common Stock	100K	$1.84	Direct	F4
holding	ADVM	Stock Option (Right to Buy)							Jun 3, 2022	Common Stock	75K	$1.39	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of September 9, 2019, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of September 9, 2019, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F2	Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 16, 2021, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of February 16, 2021 subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F3	Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of July 15, 2021, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of July 15, 2021 subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F4	Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of December 2, 2021, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of December 2, 2021 subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F5	Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 18, 2022, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of February 18, 2022 subject to the Reporting Person's continued service with the Issuer on each such vesting date.